Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach
about
Population pharmacokinetics of meropenem during continuous infusion in surgical ICU patients.Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Are standard doses of piperacillin sufficient for critically ill patients with augmented creatinine clearance?Pharmacokinetics and pharmacodynamics of continuous-infusion meropenem in pediatric hematopoietic stem cell transplant patientsDevelopmental pharmacokinetics of piperacillin and tazobactam using plasma and dried blood spots from infants.Pharmacodynamic and pharmacokinetic considerations in the treatment of critically Ill patients infected with carbapenem-resistant Enterobacteriaceae.Sparing carbapenem usage.Population Pharmacokinetics of High Dose Continuous Infusion Meropenem and Considerations for the Use in the Treatment of Infections due to KPC-Producing Klebsiella pneumoniae.Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study.Pharmacokinetics and pharmacodynamics of continuous infusion meropenem in overweight, obese, and morbidly obese patients with stable and unstable kidney function: a step toward dose optimization for the treatment of severe gram-negative bacterial inβ-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.An international, multicentre survey of β-lactam antibiotic therapeutic drug monitoring practice in intensive care units.
P2860
Q30316322-509E7B8E-9E3F-490C-A7CA-2D787EA65F36Q33798203-6940EF18-F9A8-4755-9579-1F0186214A48Q34274190-5234ACED-AD8D-4B12-B86A-20641E13FE29Q34894900-55F550F4-1E23-4D5E-9862-4D69B01E4EA5Q35124710-8EA36C67-9223-472F-BC11-7B2CA3119281Q35960828-3229C5C9-AA0E-4D05-A696-FD3B4649A359Q37713019-6BED270E-EE10-4903-94AA-127E768486F7Q38944862-4C14DD8B-DFFD-42C5-8477-D58F9570F421Q39388468-655FB0A3-9ED6-40AA-9EF7-4B19A84708CBQ40112541-8CE334F9-7CDF-4150-8247-B76F230CAB1BQ40189852-8377EEAE-3C4E-4336-B744-52B254E0C0F9Q41349399-BB51AA08-B8AB-4FA5-8681-EBA4007F316BQ42099202-C9830697-1C7F-4854-8B36-7F808FE10404Q42232248-18A265E9-DD11-48DF-B605-BA4F50FE7696
P2860
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Dosing nomograms for attaining ...... harmacodynamics-based approach
@ast
Dosing nomograms for attaining ...... harmacodynamics-based approach
@en
type
label
Dosing nomograms for attaining ...... harmacodynamics-based approach
@ast
Dosing nomograms for attaining ...... harmacodynamics-based approach
@en
prefLabel
Dosing nomograms for attaining ...... harmacodynamics-based approach
@ast
Dosing nomograms for attaining ...... harmacodynamics-based approach
@en
P2860
P356
P1476
Dosing nomograms for attaining ...... harmacodynamics-based approach
@en
P2093
Mario Furlanut
Pierluigi Viale
P2860
P304
P356
10.1128/AAC.01291-12
P407
P577
2012-10-08T00:00:00Z